Market Cap
$246.2M
QTTB
Q32 Bio Inc.
$8.39 ▲ +1.70%
Prev close $8.25Market cap$246.2M
ConsensusStrong Buy
12-mo target$39.60 (+372.0%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)12 New Institutional Positions4 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on QTTB right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
45 funds
Inst. Value
$73.9M
Inst. Activity
12 buys / 4 sells
Insider Activity
$30.0M buy / $350.6K sell
Insider Net $
$29.6M
SEC Reports
13
Press Releases
1
Price chart 30d -38.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 trading_halt
Sep 14, 2026 SEC Halt Resumed: QTTB — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-30T13:30:37.000Z | Resumed 2026-09-30T13:35:37.000Z
Q32 Bio announced the appointment of Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Develo
8-K — Impact 3/10
Q32 Bio CEO and CFO sold a combined $229K in open-market sales on August 25, 2026, at $16.56 per share. The total value
CLUSTER — Impact 2/10
Aug 25, 2026 Insider
Kalowski Lee sold 3,972 shares
CFO and President @ $16.56 ($65.8K)
Aug 25, 2026 Insider
Morrison Jodie Pope sold 9,845 shares
CEO @ $16.56 ($163.0K)
Aug 25, 2026 Insider
Aug 5, 2026 SEC Violette Shelia M. sold 2,798 shares
Chief Scientific Officer @ $16.56 ($46.3K)
Q32 Bio reported positive bempikibart 36-week topline results from the SIGNAL-AA Phase 2a trial in severe/very severe al
8-K — Impact 7/10
Q32 Bio priced a $200 million underwritten public offering of common stock and pre-funded warrants, representing massive
Impact 7/10
Analyst ratings buy % +22.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 28, 2026 | Jefferies | INITIATE | Buy | 53% |
| Aug 24, 2026 | Morgan Stanley | INITIATE | Overweight | 55% |
| Jul 28, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jul 13, 2026 | Oppenheimer | MAINTAIN | Outperform | 52% |
| Jul 13, 2026 | Wells Fargo | UPGRADE | Overweight | 54% |
| May 22, 2026 | Mizuho | INITIATE | Outperform | 52% |
| May 18, 2026 | Cantor Fitzgerald | INITIATE | Overweight | 49% |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jul 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| Jun 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 3 | 4 | 2 | 0 | 0 | 78% | |
| Feb 1, 2026 | 3 | 3 | 2 | 0 | 0 | 75% |
Price targets
Where 5 covering analysts think QTTB trades over the next 12 months.
$39.60 +372.0% upside Strong Buy
Current$8.39 Low$29.00 Median$36.00 High$59.00 5 analysts
$29.00$59.00
Analyst rating Strong Buy· 1.2/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
13 SEC filing reports analyzed · 4 bullish, 3 bearish, 0 mixed, 6 neutral · avg impact 5.0/10.Plus 1 press releases.
NEUTRAL8-K3/10
Q32 Bio announced the appointment of Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershbe
Sep 14, 2026
NEUTRALCLUSTER2/10
Q32 Bio CEO and CFO sold a combined $229K in open-market sales on August 25, 2026, at $16.56 per sha
Aug 28, 2026
BULLISH8-K7/10
Q32 Bio reported positive bempikibart 36-week topline results from the SIGNAL-AA Phase 2a trial in s
Aug 5, 2026
NEUTRALEFFECT3/10
Q32 Bio's S-3 shelf registration (File No. 333-297027) became effective on July 13, 2026, allowing t
Jul 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
trading_halt
Halt Resumed: QTTB — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-30T13:30:37.000Z | Resumed 2026-09-30T13:35:37.000Z
Sep 30, 2026
trading_halt
Trading Halt: QTTB — LUDP (Volatility Trading Pause)
Q32 Bio Inc. | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 30, 2026
short_volume
Short Volume: QTTB — 55.2% short (1.1M / 1.9M)
Short: 1,071,206 | Exempt: 77,967 | TRF Vol: 1,941,076 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: QTTB — 71.9% short (0.4M / 0.5M)
Short: 388,279 | Exempt: 0 | TRF Vol: 540,240 | Short Ratio: 71.9% | Off-exchange volume (dark pool + OTC)
Sep 14, 2026
short_volume
Short Volume: QTTB — 58.8% short (0.3M / 0.5M)
Short: 313,080 | Exempt: 0 | TRF Vol: 532,859 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.34 | $-0.42–$-0.27 | 44.2% | -3.1% | 2↑ 1↓ | $0.0B | 6 |
| Next Q | $-0.30 | $-0.36–$-0.23 | -106.6% | -3.4% | 2↑ 1↓ | $0.0B | 6 |
| Current FY | $-1.52 | $-1.64–$-1.37 | -162.7% | -2.1% | 2↑ 1↓ | $0.0B | 6 |
| Next FY | $-2.14 | $-3.14–$-1.54 | -41.0% | -17.7% | 3↑ 0↓ | $0.0B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.335 | — |
| 7d ago | $-0.332 | -0.003 |
| 30d ago | $-0.325 | -0.010 |
| 60d ago | $-0.382 | +0.047 |
| 90d ago | $-0.406 | +0.071 |
Institutional ownership
Which big funds own QTTB (from quarterly 13F filings) and who is adding or trimming.
45 institutional holders with $73.9M total value (5,819,894 shares) as of 2026-Q2. Top holders: ROYAL, RA, Point72. Net buying activity: 12 institutions added/increased vs 4 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| ROYAL BANK OF CANADA | 43 | $0.00 | 0.0% | NEAR_EXIT -98.4% |
| RA CAPITAL MANAGEMENT, L.P. | 2,332,457 | $29.7M | 40.2% | NEW |
| Point72 Asset Management, L.P. | 1,173,396 | $14.9M | 20.2% | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | 518,803 | $6.6M | 8.9% | ADD +69.3% |
| Woodline Partners LP | 286,212 | $3.6M | 4.9% | — |
| AMERICAN CENTURY COMPANIES INC | 272,752 | $3.5M | 4.7% | DOUBLED +1353.1% |
| RENAISSANCE TECHNOLOGIES LLC | 179,600 | $2.3M | 3.1% | DOUBLED +110.6% |
| JANE STREET GROUP, LLC | 162,747 | $2.1M | 2.8% | DOUBLED +148.1% |
| GEODE CAPITAL MANAGEMENT, LLC | 122,690 | $1.6M | 2.1% | ADD +43.7% |
| CITADEL ADVISORS LLC | 120,663 | $1.5M | 2.1% | DOUBLED +679.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| ROYAL BANK OF CANADA | NEAR_EXIT | 2,744 | 43 | -98.4% | — |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 2,332,457 | — | $29.7M |
| Point72 Asset Management, L.P. | NEW | — | 1,173,396 | — | $14.9M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 306,401 | 518,803 | +69.3% | $6.6M |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | 18,770 | 272,752 | +1353.1% | $3.5M |
| JANE STREET GROUP, LLC | DOUBLED | 65,599 | 162,747 | +148.1% | $2.1M |
| CITADEL ADVISORS LLC | DOUBLED | 15,481 | 120,663 | +679.4% | $1.5M |
| BlackRock, Inc. | ADD | 86,147 | 118,507 | +37.6% | $1.5M |
| MARSHALL WACE, LLP | ADD | 52,440 | 67,045 | +27.9% | $854.2K |
| VANGUARD FIDUCIARY TRUST CO | ADD | 49,995 | 66,217 | +32.4% | $843.6K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 36 transactions. Net $29.6M — $30.0M bought, $350.6K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | Kalowski Lee | CFO and President | SELL | 3,972 | $16.56 | $65.8K |
| Aug 25, 2026 | Morrison Jodie Pope | CEO | SELL | 9,845 | $16.56 | $163.0K |
| Aug 25, 2026 | Violette Shelia M. | Chief Scientific Officer | SELL | 2,798 | $16.56 | $46.3K |
| Jul 16, 2026 | Kalowski Lee | CFO and President | AWARD | 53,250 | — | — |
| Jul 16, 2026 | Morrison Jodie Pope | CEO | AWARD | 132,000 | — | — |
| Jul 16, 2026 | Violette Shelia M. | Chief Scientific Officer | AWARD | 37,500 | — | — |
| Jun 30, 2026 | Manke Isaac | Director | EXERCISE | 53,521 | $2.80 | $149.9K |
| Jun 12, 2026 | TZIANABOS ARTHUR | Director | AWARD | 10,826 | — | — |
| Jun 12, 2026 | Lundberg Sven Ante | Director | AWARD | 10,826 | — | — |
| Jun 12, 2026 | LAPORTE KATHLEEN | Director | AWARD | 10,826 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for QTTB.
Shares short
3,772,651
Settlement Sep 15, 2026
Change vs prior
+6.1%
Semi-monthly cycle
Days to cover
5.2
At avg daily volume
Of shares outstanding
≈12.7%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Sep 30, 2026 | LUDP | Volatility Pause | Resumed |
All QTTB filing & press-release reports (14)
- 8-K reportSep 14, 2026
- CLUSTER reportAug 28, 2026
- 8-K reportAug 5, 2026
- PRESS-RELEASE reportJul 15, 2026
- EFFECT reportJul 14, 2026
- 8-K reportJul 13, 2026
- 8-K reportJul 13, 2026
- S-3 reportJun 26, 2026
- CLUSTER reportJun 2, 2026
- 8-K reportMay 5, 2026
- 8-K reportApr 24, 2026
- 424B5 reportApr 24, 2026
- 424B5 reportMar 27, 2026
- CLUSTER reportFeb 28, 2026